NEW YORK, Feb. 28, 2017 -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Psychemedics Corporation (“Psychemedics” or the “Company”) (NASDAQ:PMD) and certain of its officers, on behalf of a class who purchased Psychemedics securities between February 28, 2014 and January 30, 2017, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/pmd.
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.
The Complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) through its affiliate Psychemedics Brasil Exames Toxicológicos Ltda., Psychemedics engaged in anticompetitive conduct to maintain a monopoly over the Brazilian market in violation of the law; (2) effectively, Psychemedics lacked effective internal controls over financial reporting; and (3) consequently, Psychemedics’ public statements were materially false and misleading at all relevant times.
On January 31, 2017, it was revealed that Psychemedics Brasil Exames Toxicológicos Ltda., Psychemedics’ local representative in Brazil, was ordered to compensate Omega Laboratories, Inc. USA for losses caused by anticompetitive practices used for “preventing other companies from accessing (the) market,” on January 20, 2017. Following this news, Psychemedics stock dropped during intra-day trading on January 31, 2017.
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: www.bgandg.com/pmd or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Psychemedics you have until April 3, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact: Bronstein, Gewirtz & Grossman, LLC Peretz Bronstein or Yael Hurwitz 212-697-6484 | [email protected]


Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals
Anthropic CEO Meets Trump Officials to Discuss Powerful New AI Model Mythos
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries”
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs
How Technology Is Reshaping Modern Business: From Operations to Customer Experience
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 



